` SGMO (Sangamo Therapeutics Inc) vs S&P 500 Comparison - Alpha Spread

SGMO
vs
S&P 500

Over the past 12 months, SGMO has outperformed S&P 500, delivering a return of +23% compared to the S&P 500's +13% growth.

Stocks Performance
SGMO vs S&P 500

Loading
SGMO
S&P 500
Add Stock

Performance Gap
SGMO vs S&P 500

Performance Gap Between SGMO and GSPC
HIDDEN
Show

Performance By Year
SGMO vs S&P 500

Loading
SGMO
S&P 500
Add Stock

Competitors Performance
Sangamo Therapeutics Inc vs Peers

S&P 500
SGMO
ABBV
AMGN
GILD
VRTX
Add Stock

Sangamo Therapeutics Inc
Glance View

Market Cap
111.5m USD
Industry
Biotechnology

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. The company is headquartered in Brisbane California, California and currently employs 431 full-time employees. The company went IPO on 2000-04-06. The firm focuses on leveraging its optimized zinc finger (ZF) technology, which is a differentiated tool used to develop genomic medicines, including allogeneic cell therapies and in vivo genome engineering therapies. Its product candidates include Isaralgagene civaparvovec, also known as ST-920, its wholly owned gene therapy product candidate for the treatment of Fabry disease; SAR445136, its ZF nuclease, gene-edited cell therapy product candidate for the treatment of sickle cell disease (SCD); TX200, its wholly owned Chimeric Antigen Receptor (CAR) engineered regulatory T cell (CAR-Treg), cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; Giroctocogene fitelparvovec, also known as SB-525, is a gene therapy product candidate for the treatment of moderately severe to severe hemophilia A.

SGMO Intrinsic Value
HIDDEN
Show
Back to Top